Suzhou KP Chemical Assists In The Development Of COVID-19 Drug-- Synthesis Of Remdesivir Intermediate

The FDA issued an emergency authorization for Gilead Scientific's antiviral drug Remdesivir, allowing the drug to be used for the treatment of suspected and diagnosed children and adults with COVID-19 in severely ill hospitals. 5 and 10 days of treatment time will be allowed.
On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' antiviral drug remdesivir for the treatment of hospitalized COVID-19 patients, making it the first officially approved COVID-19 treatment drug in the United States.

Nature( 2016, 531(7594), 381-385 ) reports on the synthesis method of Remdesivir, see the picture below.

In patent WO2016069825, in the example of compound 1 and compound 2 used to prepare compound 3, rare earth compound anhydrous lanthanum chloride (Lacl3), anhydrous cerium chloride (CeCl3), anhydrous yttrium chloride (YCl3) and anhydrous neodymium chloride (NdCl3) are used.

The preparation method of anhydrous Rare Earth chloride is to dissolve rare earth oxide or hydroxide in hydrochloric acid to obtain rare earth chloride solution. After evaporating and concentrating the solution to a RE₂O₃ content of 40% to 50%, cooling and crystallizing, and drying at 100°C, hydrated rare earth chloride can be obtained. Hydrated rare earth chloride generally has 6 bound waters, and its crystal water can be removed by heating. Anhydrous rare earth chloride is prepared industrially by vacuum dehydration in the presence of ammonium chloride.
Anhydrous rare earth chloride is the superior product of Suzhou KP Chemical Co., Ltd. We can provide these four products. Please contact info@szwww.kpchemmaterial.com or 086-18915544907.